Status:
TERMINATED
Ticagrelor CytoSorb Hemoadsorption
Lead Sponsor:
CytoSorbents, Inc
Conditions:
Emergent Cardiothoracic Surgery
Bleeding
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
TISORB is a study to show that the CytoSorb device removes ticagrelor from blood during surgery in patients who need emergency surgery on their heart. The hypothesis of TISORB is that removal of ticag...
Eligibility Criteria
Inclusion
- Cardiothoracic surgery requiring cardiopulmonary bypass ≤ 48 hours following the last dose of ticagrelor.
Exclusion
- Any cardiothoracic surgery \> 48 hours after last dose of ticagrelor.
Key Trial Info
Start Date :
October 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 4 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04131959
Start Date
October 29 2019
End Date
May 4 2021
Last Update
March 9 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth Hospital
Birmingham, England, United Kingdom, B15 2TH
2
Blackpool Victoria Hospital
Blackpool, England, United Kingdom, FY3 8NR
3
Harefield Hospital
Harefield, England, United Kingdom, UB9 6JH
4
Manchester Royal Infirmary
Manchester, England, United Kingdom, M13 9WL